Pharmacologic inhibition of the BTK-IDO axis and deletion of BTK/IDO genes led to the robust differentiation of inflammatory DCs and promoted anti-tumor T cell responses both in vitro and in vivo [271]. This evidence concerns the gene BTK and neoplasm.